EPO and Bicycling

News & Results

06/27/2003| 0 comments
by Chad Asplund, MD

EPO and Bicycling

A discussion of EPO and the future of doping in cycling.

Recently our sport has been riddled with scandal revolving around the use of performance enhancing supplements.   From the ?Festina affair? in 1998, to the 2002 Giro, we now all know what non-negative means, and those accusations are that if you are winning in cycling, you are probably doping.   Testing during the 2000 Tour de France revealed the presence of various performance enhancers (drugs and supplements) in the urine of 45% of the competitors that were tested.   The most commonly discussed of these performance-enhancing supplements is erythropoietin (EPO).   This article will discuss what EPO is, how it is being used, detection tests, and the future of doping in cycling. <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /?>


EPO is a hormone naturally produced by the kidneys when oxygen supply is low.   Thus natural EPO concentrations in the blood increase when a cyclist is anemic, has been training at altitude, or has been exposed to pollution or second-hand cigarette smoke.   EPO acts as a signal for the bone marrow to increase the rate at which red blood cells are made and released into the circulation (this can be measured as the reticulocyte count).   The increase in number of red blood cells leads to an increased oxygen supply to the tissues throughout the body.   This oxygen rich blood then acts as a signal to the kidneys to stop producing EPO keeping the hematocrit within the normal range.


Synthetic EPO has been made by inserting the human gene responsible for EPO into a cell within a laboratory and then stimulating the cell to produce recombinant EPO (r-EPO).   r-EPO was developed by pharmaceutical companies for treating patients with kidney failure, or those undergoing cancer chemotherapy.   R-EPO assists these patients in raising their hematocrit and oxygen carrying capacity, ameliorating the symptoms of their chronic disease.   Early clinical trials showed that r-EPO is capable of increasing the hematocrit (index of red blood cell level) by 3-4% over 3-4 weeks.


It is documented that the endurance process is improved in athletes with an increased red blood cell level, and thus an increased oxygen carrying capacity.   This occurs whether the red blood cells are increased via transfusion, or artificially with r-EPO.   Improvements in performance are greatest about 3 weeks after r-EPO injection.


Although no direct links have been made between EPO and cycling deaths, anecdotal evidence is abundant.   Too much r-EPO can increase hematocrit to the point that overall blood viscosity is increased making the blood like sludge.   This thickened blood could cause the heart to work excessively hard, which may lead to a heart attack.   Increasing hematocrit also increases the risk in the cyclist for clotting events, raises blood pressure, and resultant iron overload can ultimately lead to organ failure.   Evidence has shown that long term EPO use may also possibly contribute to blood borne cancers.


Despite the potentially fatal risks, it is apparent that many professional cyclists may be using EPO to improve performance.   Because EPO potentially gives an unfair advantage in competition, it


Your comments
Your comments
sign up or login to post a comment